Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.
about
Eating disorders in schizophrenia: implications for research and managementEffect of atypical antipsychotics on fetal growth: is the placenta involved?RNA sequencing reveals a slow to fast muscle fiber type transition after olanzapine infusion in ratsAcute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistanceAn evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapineMetabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.The potential role of appetite in predicting weight changes during treatment with olanzapine.First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents.A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychoticsAtypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the ratAtypical antipsychotics and the neural regulation of food intake and peripheral metabolism.A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistanceAcute Metabolic Effects of Olanzapine Depend on Dose and Injection Site.Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications.Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs.Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice.Hypothalamic control of energy and glucose metabolism.Acute hyperglycemia associated with short-term use of atypical antipsychotic medications.Atypical antipsychotic-induced metabolic disturbances in the elderly.In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact.Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression.Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact.Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats.Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C57BL/6J mice.A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics
P2860
Q21284525-E0298184-34DD-43A6-898F-6557EA85DA00Q27012948-000D92E5-3491-430A-9102-638A6CF3D220Q27309270-55A65930-6D24-40C2-B98D-8090BC10033CQ27323282-D7214296-0373-41AD-8B74-D8FDF831BCF6Q28543222-1E6202CD-F0D7-4445-A5E2-DE096F2FEB8FQ30459096-799F930E-821E-49C9-A35F-1667B10B9FD8Q33692484-352E4103-F44F-44C2-AB57-B46758382315Q33845881-682497DF-E02A-4DCA-BFFF-25E5D45CE876Q33862577-240DE22E-EA79-4886-9644-106D4AA65CE1Q33888821-16DD8621-A01B-49E9-9A04-DF1CD535A5B9Q34117015-56431C1E-C933-4F46-A036-E576922B611BQ34376884-09D729D8-0DCB-457D-9BC0-9869368CD9D3Q35004010-A17BD76E-31A8-4BF7-8E79-6DEE4BF4522DQ35115972-6E91842F-40B5-4664-8959-34539DB0BD7BQ35156543-1E365623-B101-40FC-90B9-FF7BCA1738A1Q35757166-E9059AC5-C303-40A8-833F-96900C1DD543Q36371905-6DA80FA2-2B57-4151-96A5-CF35625A1E8AQ36383322-95E51D13-5592-454D-9EAB-8B0817CA27FAQ36817242-9F9023DA-5B0D-47F5-9C88-21DD65021464Q37193192-7EF9E5BF-1F5A-4D64-8759-83A21E450FC8Q37598227-9A188240-5D71-41B8-8D0B-0DE083E83507Q37892968-09D632DE-0E99-4B3B-BC0E-C6419CE44868Q38176569-AAD6AAD4-DA17-45A5-9E01-6B42ECF84CFEQ38183274-8D46AE7D-447C-41FA-8210-13EB9EEDE2E8Q43090127-0EB23070-8B83-43E7-9495-A147726660E5Q47188807-1A676EEA-056F-4BB5-9440-186400535CF0Q47581724-9930032D-5156-4CFC-A713-FF2BF857DAB1Q47596558-74522851-3293-48BD-8003-DD70021AB7CDQ47762878-9B032DD2-B634-4496-8C0B-6D0384F3DB19Q54662194-839F7373-C76C-48A9-B44E-06BB61D85294Q55405731-9C248EAB-81FA-494E-AAD9-4C542581DB2DQ59206898-C8915115-881F-4671-A2AB-F12D428C8EC8
P2860
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Insulin resistance and decreas ...... ute olanzapine administration.
@en
Insulin resistance and decreas ...... ute olanzapine administration.
@nl
type
label
Insulin resistance and decreas ...... ute olanzapine administration.
@en
Insulin resistance and decreas ...... ute olanzapine administration.
@nl
prefLabel
Insulin resistance and decreas ...... ute olanzapine administration.
@en
Insulin resistance and decreas ...... ute olanzapine administration.
@nl
P2093
P50
P1476
Insulin resistance and decreas ...... ute olanzapine administration.
@en
P2093
Araba F Chintoh
Jose N Nobrega
Paul J Fletcher
Steve W Mann
Tony A Cohn
P304
P356
10.1097/JCP.0B013E318184B4C5
P407
P577
2008-10-01T00:00:00Z